CARMAT announces a fundraising of 15 million euros

CARMAT, a company specializing in the development of a total artificial heart, is launching a €15 million fundraising operation. This operation consists of an offer to specialized investors and a public offer via the PrimaryBid platform. The price set for the issue of the new shares is 3 euros per share. Subscriptions for the public offer will be closed on May 16, 2024 at 11 p.m. and those for the reserved offer the next day.

The main objective of this fundraising is to strengthen the company's equity and support its short-term working capital needs. This will allow CARMAT to maintain its activities until mid-August 2024, including the continuation of its production and commercial development as well as its EFICAS clinical trial in France. Nevertheless, the company anticipates an additional financial need of around €30 million for the next twelve months.